Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2737–2760 of 3,580 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: patch Clear all

Conditions: Restless Legs Syndrome
Interventions: Rotigotine 1 mg/24 h, Rotigotine 2 mg/24 h, Rotigotine 3 mg/24 h; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Culver City, California

Conditions: Opioid-use Disorder, Opioid Use, Opioid Dependence, Opioid Abuse, Medication Assisted Treatment, Infusion Catheter, Wound, Lidopatch, Ambu ACTion, Pregnancy Related, Cesarean Section
Interventions: Lidocaine patch, Ambu ACTion pump, 0.125% bupivacaine at 8cc/hr; Drug · Device
Lead sponsor: WellSpan Health; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: York, Pennsylvania

Conditions: Lip and Oral Cavity Cancer, Oropharyngeal Cancer, Stage 0 Lip and Oral Cavity Cancer, Stage 0 Oropharyngeal Cancer, Tongue Cancer
Interventions: Ad5CMV-p53 gene, laboratory biomarker analysis; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Atopic Dermatitis
Interventions: Ruxolitinib Cream, Vehicle Cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 18
States / cities: Little Rock, Arkansas • Fountain Valley, California • Fremont, California + 15 more

Conditions: Application Site Perspiration
Interventions: Skin Patch; Device
Lead sponsor: Larkin Community Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Hollywood, Florida

Conditions: Smoking Cessation
Interventions: smoking cessation counseling, Nicotine patch, alphanumeric pager; Behavioral · Drug · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 80 Years
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Healthy Volunteers
Interventions: Treatment A: ORTHO EVRA patch (NGMN + EE) with an adhesive overlay, Treatment B: ORTHO EVRA patch (NGMN + EE) without an overlay; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Barretts Esophagus With High Grade Dysplasia, Barrett Adenocarcinoma
Interventions: Acell MatriStem® Surgical Matrix; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cystic Fibrosis, Adherence, Medication
Interventions: Patch Cap, Patch App; Device
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 12 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Current Every Day Smoker
Interventions: Computer-Assisted Smoking Cessation Intervention, Laboratory Biomarker Analysis, Nicotine Patch, Questionnaire Administration, Sham Intervention; Behavioral · Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Postherpetic Neuralgia, Pain
Interventions: Transdermal/Patch (Bupivacaine TTS [Eladur™]); Drug
Lead sponsor: Durect; Industry
Eligibility: 21 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 7
States / cities: La Jolla, California • Loma Linda, California • Santa Monica, California + 4 more

Conditions: Atopic Dermatitis (AD)
Interventions: Onabotulinum Toxin Type A - Phase 1b, Onabotulinum Toxin Type A - Phase 2; Drug
Lead sponsor: Daniel Kaplan; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Atrial Fibrillation
Interventions: Unipolar Polarity Switch Left, Unipolar Polarity Switch Right; Other
Lead sponsor: Kansas City Heart Rhythm Research Foundation; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Overland Park, Kansas

Conditions: Anxiety Disorders, Parkinson Disease
Interventions: rotigotine transdermal patch, placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 89 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Thoracic Aortic Aneurysms, Thoracic Transections, Intramural Hematoma, Pseudoaneurysm, Thoracic Aortic Dissection
Interventions: Endoluminal treament of thoracic lesions; Device
Lead sponsor: Rodney A. White, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2021
U.S. locations: 1
States / cities: Torrance, California

Conditions: Breast Cancer
Interventions: Topical Calcipotriene Ointment, Topical Vaseline; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 50 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Malignant Skin Neoplasm, Skin Disorder, Skin Neoplasm
Interventions: Quantitative Oblique Back-Illumination Microscopy, Radiation Therapy; Procedure · Radiation
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Cutaneous T Cell Lymphoma, Mycosis Fungoides
Interventions: Hypericin, Visible Light; Drug · Other
Lead sponsor: Ellen Kim, MD; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Overactive Bladder, Voiding Disorders, Incontinence, Urinary
Interventions: parasacral transcutaneous electrical nerve stimulation (PTENS), Standard Urotherapy; Device · Other
Lead sponsor: University of Utah; Other
Eligibility: 6 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Prostate Cancer
Interventions: High-resolution micro-ultrasound; Device
Lead sponsor: University of Alberta; Other
Eligibility: 18 Years and older · Male only
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2033
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cumulative Irritation
Interventions: Novel lubricant Miami w/ fragrance, Novel lubricant Miami no fragrance, KY Liquid lubricant, Astroglide Gel lubricant, Wet Platinum lubricant; Device
Lead sponsor: Church & Dwight Company, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Multiple Sclerosis
Interventions: Clinical Questionnaires, Semi-Structured Interviews, Ocrevus Zunovo; Other · Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Anal High Grade Squamous Intraepithelial Lesion
Interventions: mHRME (Mobile High resolution microendoscope), Proflavine Hemisulfate, High resolution anoscopy; Diagnostic Test · Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 3
States / cities: New York, New York • Houston, Texas

Conditions: Stable Angina, Unstable Angina, NSTEMI
Interventions: Collecting invasive FFR measurements.; Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: La Jolla, California

Search by objective public record fields.

A Follow-up Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome

The Analgesic Efficacy of Continuous Sub-fascial Bupivacaine Infusion and Lidocaine Patches in Post-cesarean Patients With Opiate Use Disorder: A Comparative Efficacy Analysis

Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx

A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis

Proteomic Analysis of Sweat in Cutaneous Conditions

Pager-Assisted Smoking Cessation Treatment

The Effect of an Adhesive Overlay on the Delivery of Contraceptive Hormones From ORTHO EVRA® in Healthy Women

Endoscopic Mucosal Resection and Cellular Matrix

The Impact of Patch Rx Technologies on Adherence to Vitamin and Trikafta Therapies in Patients With Cystic Fibrosis

Smartphone-Delivered Attentional Bias Modification Training in Helping Patients Quit Smoking

Study of a Bupivacaine Patch (Eladur™) to Treat Post- Herpetic Neuralgia

The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis

Efficacy Rate of Unipolar Polarity Switch for Lesion Assessment in Pulmonary Vein Isolation

Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational Treatment

Physician-Sponsored IDE for the Talent Endoluminal Stent Graft System for the Treatment of Thoracic Lesions

Topical Calcipotriene Treatment for Breast Cancer Immunoprevention

Optical Imaging Scans for the Diagnosis of Skin Cancer in Patients With Lesions

Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light

Feasibility of Parasacral Transcutaneous Electrical Nerve Stimulation PTENS for Voiding Dysfunction in Peds Population

Micro-UltraSound In Cancer - Active Surveillance

14-Day Cumulative Irritation Patch Test in Subjects With Normal Skin

Ocrevus Zunovo for MS: Mixed Methods

The Effectiveness of High Resolution Microendoscopy for People Living With HIV

Evaluation of a Novel Non-Invasive Automated Fractional Flow Reserve Software System in Patients With Coronary Artery Disease